(NASDAQ: RGNX) Regenxbio's forecast annual revenue growth rate of 44.71% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 116.52%, and while it is forecast to beat the US market's average forecast revenue growth rate of 23.59%.
Regenxbio's revenue in 2026 is $161,318,000.On average, 14 Wall Street analysts forecast RGNX's revenue for 2026 to be $14,294,947,025, with the lowest RGNX revenue forecast at $7,254,288,224, and the highest RGNX revenue forecast at $20,676,999,477. On average, 10 Wall Street analysts forecast RGNX's revenue for 2027 to be $18,800,907,910, with the lowest RGNX revenue forecast at $10,652,109,756, and the highest RGNX revenue forecast at $26,646,473,778.
In 2028, RGNX is forecast to generate $25,259,907,452 in revenue, with the lowest revenue forecast at $18,871,780,230 and the highest revenue forecast at $32,317,778,102.